Our future research interests will mainly focus on developing new synthetic technology to construct small molecule agents for biomedical research, particularly cancer research, including:

1) developing novel catalytic C-H and C-C bond activation methods for efficient small-molecule library synthesis;

2) establishing efficient synthetic routes to access natural products with high potent anticancer activity and their unnatural analogues;

3) evaluating in vitro and in vivo efficacy of rationally designed natural product analogues and understanding the origins of the selectivity in the cell-killing process. Our research goal is to harness the power of transition-metal catalysts to ease the discovery of new cancer therapeutics and ultimately address the pressing needs in the development of anti-cancer drug.